Evidence map›Paper›PMID 37527178›Full record

ArticleMolecular cancer research : MCR2023

Stromal DDR2 Promotes Ovarian Cancer Metastasis through Regulation of Metabolism and Secretion of Extracellular Matrix Proteins.

Angela M Schab, Molly M Greenwade, Elizabeth Stock, Elena Lomonosova, Kevin Cho, Whitney R Grither, Hollie Noia, Daniel Wilke, Mary M Mullen, Andrea R Hagemann and 12 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 1 country.

Angela M Schab *Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri.ORCID 0000-0003-1569-2452
Molly M Greenwade *Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri.ORCID 0009-0007-7753-9388
Elizabeth Stock *Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri.ORCID 0000-0001-9045-4900
Elena LomonosovaDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri.ORCID 0009-0005-0970-4615
Kevin ChoCenter for Metabolomics and Isotope Tracing, Department of Chemistry, Department of Medicine, Washington University, St. Louis, Missouri.ORCID 0000-0002-3041-3506
Whitney R GritherDepartment of Obstetrics and Gynecology, Barnes Jewish Hospital, Washington University, St. Louis, Missouri.ORCID 0000-0003-1053-6469
Hollie NoiaDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri.ORCID 0009-0003-0148-8124
Daniel WilkeDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri.ORCID 0009-0003-8331-1030
Mary M MullenDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri.ORCID 0000-0002-2976-5141
Andrea R HagemannDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri.ORCID 0000-0002-3484-0046
Ian S HagemannDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri.ORCID 0000-0002-3855-9745
Premal H ThakerDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri.ORCID 0000-0002-0568-6959
Lindsay M KurokiDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri.ORCID 0000-0002-2141-7310
Carolyn K McCourtDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri.ORCID 0000-0003-2229-8971
Dineo KhabeleDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri.ORCID 0000-0002-5151-5210
Matthew A PowellDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri.ORCID 0000-0002-9001-3862
David G MutchDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri.ORCID 0000-0002-6921-1581
Peinan ZhaoDepartment of Obstetrics and Gynecology, Barnes Jewish Hospital, Washington University, St. Louis, Missouri.ORCID 0009-0006-0883-0190
Leah P ShriverCenter for Metabolomics and Isotope Tracing, Department of Chemistry, Department of Medicine, Washington University, St. Louis, Missouri.ORCID 0000-0001-5673-0940
Gary J PattiCenter for Metabolomics and Isotope Tracing, Department of Chemistry, Department of Medicine, Washington University, St. Louis, Missouri.ORCID 0000-0002-3748-6193
Gregory D LongmoreDivision of Oncology, Department of Medicine Washington University, St. Louis, Missouri.ORCID 0000-0001-7568-8151
Katherine C FuhDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University, St. Louis, Missouri.ORCID 0000-0002-7693-2694
Washington University in St. Louis · USBarnes-Jewish Hospital · USUniversity of California, San Francisco · US

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
REPRODUCTIVE SCIENTIST TRAINING PROGRAMK12HD000849 · NICHD · WASHINGTON UNIVERSITY · PI Danny J Schust · 1988 to 2026
$33.2M
Washington University Nutrition Obesity Research CenterP30DK056341 · NIDDK · WASHINGTON UNIVERSITY · PI Dominic N Reeds · 1999 to 2026
$30.2M
Developing Metabolomic Technologies to Advance Environmental Exposure AnalysisR35ES028365 · NIEHS · WASHINGTON UNIVERSITY · PI PATTI, GARY J · 2017 to 2024
$5.9M
MOLECULAR ONCOLOGY TRAINING GRANTT32CA113275 · NCI · WASHINGTON UNIVERSITY · PI Matthew J Walter · 2006 to 2026
$5.7M
Leader cell development and function in Breast Tumor Collective MigrationR01CA254060 · NCI · WASHINGTON UNIVERSITY · PI Gregory D. Longmore, Amit Pathak · 2022 to 2026
$2.6M
Integrated Translational Genoproteomics Center at Washington UniversityU10CA180860 · NCI · WASHINGTON UNIVERSITY · PI CHUNG, CHRISTINE H, ELLIS, MATTHEW J · 2014 to 2018
$2.6M
Role of the microenvironment in ovarian cancer metastasisR01CA234553 · NCI · WASHINGTON UNIVERSITY · PI FUH, KATHERINE CYNTHIA · 2019 to 2023
$2.1M
Tumor stromal effects of DDR2 in metastasis regulationR01CA223758 · NCI · WASHINGTON UNIVERSITY · PI LONGMORE, GREGORY D. · 2018 to 2022
$1.9M
NOVEL SMALL MOLECULE INHIBITION OF DDR2 TO PREVENT BREAST CANCER METASTASISR01CA196205 · NCI · WASHINGTON UNIVERSITY · PI LONGMORE, GREGORY D. · 2015 to 2019
$1.7M
NCATS NIH HHS UL1 TR000448NCI NIH HHS 5U10CA180860–04 U10NCI NIH HHS P30 CA091842NCI NIH HHS R01 CA196205NCI NIH HHS R01 CA223758NCI NIH HHS R01:CA223758NCI NIH HHS R01 CA234553NCI NIH HHS R01CA234553NCI NIH HHS R01 CA254060NCI NIH HHS T32 CA113275NCI NIH HHS T32CA113275NCI NIH HHS U10 CA180860NICHD NIH HHS K12 HD000849NIDDK NIH HHS P30 DK056341NIEHS NIH HHS R35ES028365
6 · The paper itself

Abstract

Ovarian cancer is the leading cause of gynecologic cancer-related deaths. The propensity for metastasis within the peritoneal cavity is a driving factor for the poor outcomes associated with this disease, but there is currently no effective therapy targeting metastasis. In this study, we investigate the contribution of stromal cells to ovarian cancer metastasis and identify normal stromal cell expression of the collagen receptor, discoidin domain receptor 2 (DDR2), that acts to facilitate ovarian cancer metastasis. In vivo, global genetic inactivation of Ddr2 impairs the ability of Ddr2-expressing syngeneic ovarian cancer cells to spread throughout the peritoneal cavity. Specifically, DDR2 expression in mesothelial cells lining the peritoneal cavity facilitates tumor cell attachment and clearance. Subsequently, omentum fibroblast expression of DDR2 promotes tumor cell invasion. Mechanistically, we find DDR2-expressing fibroblasts are more energetically active, such that DDR2 regulates glycolysis through AKT/SNAI1 leading to suppressed fructose-1,6-bisphosphatase and increased hexokinase activity, a key glycolytic enzyme. Upon inhibition of DDR2, we find decreased protein synthesis and secretion. Consequently, when DDR2 is inhibited, there is reduction in secreted extracellular matrix proteins important for metastasis. Specifically, we find that fibroblast DDR2 inhibition leads to decreased secretion of the collagen crosslinker, LOXL2. Adding back LOXL2 to DDR2 deficient fibroblasts rescues the ability of tumor cells to invade. Overall, our results suggest that stromal cell expression of DDR2 is an important mediator of ovarian cancer metastasis. IMPLICATIONS: DDR2 is highly expressed by stromal cells in ovarian cancer that can mediate metastasis and is a potential therapeutic target in ovarian cancer.

Indexed as

Discoidin Domain Receptor 2Ovarian NeoplasmsCollagenExtracellular MatrixExtracellular Matrix ProteinsFemaleHumansPhosphorylationCollagenDDR2 protein, humanDiscoidin Domain Receptor 2Extracellular Matrix Proteins

Identifiers

PMID37527178
PMCPMC10832402
OpenAlexW4385454057

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.